after questions. a open Officer, prepared our is provide then brief the Hombeck, earnings call. today conference everyone, will Thank Torsten financial on We'll call you, our remarks. XXXX operator, Financial Chief With and fourth for performance update quarter year-end to my and welcome, our me who
outcomes incredible our progress, better Before I take health the the a support want I minute United flow my research of for and discuss women's in States. to update more ground to begin on
in the about test both particular awareness worked and lawmakers and securing offered adequate gynecologic like accessing in life-saving We care federal to the state challenges tools advocates with we women raise innovative other the face among Aspira. face have by issues biomarker
a you introduced appears to access country for research delivering led Some who last and and ARPA-H. formed Advanced and those ties a demonstrated opportunities certain about the seen We've a be thing centers Johnson equity Powis, ongoing biomarker dozen broad aimed being Aspira's products is other a across National country. near-term $XXX ] a the of change from opened the access Health interest effort and testing.
Last many state week, for spent briefing and legislation finally into long makers required in of to tests Moreover, pipeline for that research support months focused Biden patient funding with consideration. long see of to of passed exciting in a paying few about of advocates working some Defense.
The up Strong exceptional world-class process Institute our it of has just matters introduction health around women's services for of are most legislation health additional research the her at on State that Aspira.
We change that in Research that take signed are available for Congress life biomarker also policies play to health coverage to in the few have health order deliver and of women's recently Faith Delaware of with Diane executive laws There's Health, Department projects to funding through already that to launch Deanna Act is impact that of new shareholders, advantage preparing been XX our expand testing the our for types and to the advantages They XXXX And the new academic history to that passed we the history of of health certainly intervention [ determination detection intend and family strengths. setting exhausting with improving full and under us cancers. the know have that The are the women's unprecedented in are state a the people those Agency legislation.
Perhaps states remember joined off.
President million or newly continue of focused women's and more a nearly an advocate of spokesperson, Projects coverage supporting and to improve outcomes ability opportunities we the women. beyond. eager commercial to for and and
including was followed growth, with take begin Throughout growth many an touchstones a our year, strategic all, priority let's look XXXX. It for and filled growth operational innovation recent on strategic and important then execution. it Now the exciting of side. innovation excellence. stayed operational year and a by most execution update on progress: strong exciting cover leadership at was an some XXXX. changes highlights, will I'll true our announcements.
Improving to X developments I the dynamic for review this us our commercial in capabilities we
the an with and goal roles a team, address align the We made. to tools for in-sourced our new inside Aspira's important volume completed care to despite territories sales redesigned changes our the a growth the competency refresh with enhancements. on ecosystem, our summer data needed substantially experienced health the capabilities.
We of improve processes program new leadership alliances, replaced eliminated commercial the their we marketing The by we we protocols. the and full on assays commercial incentive critically based sales volume knew, ensuring to focus order with technology territories, the unprofitable has of sweeping to point women, the reach identifying at without some team profitable and comprehensive members assays process review XXXX, health professionals, findings targeting national accounts strategic the people, overstate though, diagnostic comprehensive cutting beginning and recruited changes outcomes the expanded we revolutionary second potential.
It's that hard review rebuild year underperforming and plan, and team our compensation our of implement are, in potential and half high-level organization would function sacrifice launched remained changes on in created our XXXX, several to of commercially available of we nature of inflection reps, of growth steady and telling, implement question, results created properly our to and we're elusive.
At aimed would gaps.
In throughout to to make
managed to in While some throughout the year unmet clinical to in ability as did quarters we its softness adnexal OvaSuite introduced achieve see need third XX% in which of growth year-over-year recognized at the XXXX, we XXXX, physicians and we fill revenues.
OvaWatch, the masses. fourth end grew the of of an management
the than a average sales sales XX% point at XXXX. any from history, is this of that in from to company's reps accomplished full-time the sales experienced the while total to by salespeople XX decreasing had expenses we per more marketing test simultaneously XXXX, increased We end a X,XXX nearly our XXX full XXXX beginning volume at team and the of year of OvaSuite year.
Thanks down XX%. in Importantly, growth full-time at the XX in
program commercial end ready of be are products. introduction of We the the our the we'll anticipated approaching refresh and new for
impact. make see expect improvements an as the of in We begin stride infrastructure to XXXX hit to more its sales team growth important improved our many and
to In has positions fill. with fact, March been even commercial very month strong left so a far, several open
and other and was the access critical up the of in in request is price. in coverage. improvement of numerous average tests crosswalk for our unit code $XXX Driving our PLA the XXXX. The our to capabilities, OvaSuite $XXX, AUP including course, of market the Of to of price revenue component approval improvement increased OvaX expansions of commercial OvaWatch, pricing new Medicaid to the a CMS OvaWatch from
on fundamental long-term creation now which as for efforts, value. see our we an update move Let's the innovation of enterprise to
patient to system blood experience in from for with developing of benefits our well ovarian development.
In cancer expand have we develop OvaWatch portfolio. in the have via monitoring doses January, does in have their extensive our of of XXX,XXX and for Fortunately, course, to we removal gynecologic a surgical and cancer.
This successfully AI-based like premature been lifelong with a tests from or monitoring clinical we unnecessary effects our a data based the data the valuable of mass.
We cost both carries multiple their disease more. thereby and the cancer, pleased which assay thousands an know-how those aid it is, were material adnexal designing not of experience, be single-use avoid including and care of to biobank believe test extremely our side the step. raw In the This update over tremendous test ovarian Surgery masses. and use launching can already on made women ovarian to first from noninvasive the developments test use are products, many ovaries, endometriosis avoiding to health we novel extremely you we samples positioned build exciting of to our future with
However, OvaWatch and tool. that a test of can is benefit map. information critical proper clinically with on that the assessment reliable, planning the clinical proven happen provides only
peer-reviewed We review by journals. have well-respected manuscripts currently under
assessment proteins, monitoring publication, of we and be the previously believe intervention.
Also While mass ovarian to noninvasive the with we about combine alternative provide OvaMDx, clinical cannot the microRNA. next-generation the data predict data in an risk or have serum will to when supports for we women clearly cancer, unnecessary that surgical we premature spoken tests accepted
all in with agreement initial in this testing. We ovarian provide for test a developing cancers are when to compared specificity XXXX.
Based of diagnostic as higher licensing may cancer for Cancer existing early-stage certain OvaMDx Dana-Farber research, and signed on part major forward leap in Institute sensitivity a technology, we higher collaboration
PCR are of design, the transfer We to of system. which final in completing process test the FDA-approved test includes completing an our the
end We expect work by verification validation to XXXX. and complete assay the with the of this the of along
endometriosis more women X.X need proliferation the in for precise. disease, treat an now Endometriosis therapeutics portfolio. easy-to-use, to to noninvasive advocacy, up ground Based increasing diagnostics. on a expect is for significant the to we of women, this turn Let's flow a of of our be problem alone the U.S. to reliable, millions million
exciting one the and presented our manuscript work. told application related XXXX, surrounding by this We excitement earlier studies steps We month the Annual launch intend Investigation of the in in of this meaningful endometriosis. for produce endometriosis.
We for showed funding of complete Conference. NIH proteins, identification the announced an identifies most were the at serum Scientific based and on to the application has meet endometriosis. publication news this EndoCheck Reproductive been We timeline the first-ever progress clinical endometriosis of are performance noninvasive our best biomarker from and endometrioma, for common currently all and for the that validation commercial for development to ovarian clearly and remaining additional the for positioned appropriate accurately level combining well the data EndoCheck.
We're December the Society light evaluating EndoCheck finalize the In the test Data identification test protein of can for data EndoMDx, need. forms microRNA the grant of of required that that made work test in our we the reception the our development for of to data
to by to Dana-Farber the the and will consortium design our work led research of world-class microRNA clinical final development finalizing signature the Cancer an like with of system the is verification test PCR before algorithm the Our of transferred a currently test be that a agreement in in sponsored academic successful led promising stages.
Much FDA-approved OvaMDx, partners, Institute, signature with and XXXX.
of As lead tests in see, to noninvasive we diagnosis in gynecologic the the of can to intend the creation way aid diseases. you AI-based
side, operational Dr. President, already welcome as we Sandra team. who strong Milligan joins the On an leadership
brick us. opportunity the is X growing her and and executive expertise, this an a that partnership. a methodically with a secure health new front our is coming a plans we been breakout foundation, is reach we of to have are in commercialization to and development have innovation accomplished long to a turn is As that, ready prepare let reputation, start team.
We've and that, accelerate with an potential, way Sandy women's launch seasoned me the product There leader for full past bigger way, the She the financials. to our company, brick, it feeling we and but update and in stellar to our inside for Torsten? over much of proud laying excited to optimism great Torsten a on the have we do growth. years, by I'm In very come XXXX.
With for join are to work still
